Navigation Links
DIA and National Pharmaceutical Council Will Host Two-Day Conference on Comparative Effectiveness Research
Date:2/28/2012

WASHINGTON, Feb. 28, 2012 /PRNewswire/ -- DIA and the National Pharmaceutical Council (NPC) will co-host the Comparative Effectiveness: A Real-World User's Guide Conference on March 14-15 at the Renaissance Washington Hotel in Washington, D.C. The conference will focus on the continued push for increased levels of evidence of comparative effectiveness research (CER) applied within health technology assessments, research planning and drug development.

Three distinguished CER researchers -- Bryan R. Luce, Senior Vice President, Science Policy, United BioSource Corp., Sean Tunis, Founder and Director, Center for Medical Technology Policy, and Brian Sweet, Executive Director, Healthcare Alliances, AstraZeneca -- will announce the first set of guiding principles developed for conducting CER studies. They also will discuss the practical application of the principles, and debate the effects the principles may have on various constituency groups, including patients, payers, and pharmaceutical industry manufacturers.

More than $1 billion dollars has been invested in comparative effectiveness research, and funding is only expected to grow in coming years. CER is designed to inform health care decisions by providing evidence on the effectiveness, benefits and harms of different treatment options. The evidence is generated from research studies that compare drugs, medical devices, tests, surgeries or ways to deliver health care. As CER becomes a standard by which patient access to new products and services is granted, the need to develop guiding principles to help yield desirable results is heightened.

The conference and sessions are timely as the complexities involved in comparative effectiveness research continue to demand principles and guidelines that can help govern and frame the entire CER enterprise. In addition, the recent creation of the Patient-Centered Outcomes Research Institute (PCORI), as well as new standards for evidence evaluation by leading payers, have made understanding the applications vitally important.

ABOUT DIA
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology and medical devices. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India and Beijing, China.


'/>"/>
SOURCE DIA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL International to Present at Cowen Healthcare Conference and Raymond James Investors Conference
2. Osseon® Announces International Distribution Agreement with Aesculap
3. NMEDA Introduces National Mobility Awareness Month for Seniors, Veterans and People with Disabilities
4. CVS Caremarks MinuteClinic to Deploy Allscripts EHR Nationally
5. SurgLine International, Inc. Update to Shareholders on Revenue Pipeline and Organizational Changes
6. National Coalition Holds Prescription Drug Take-back Day in Palm Springs Ahead of Pain Medicine Scientific Meeting
7. Access Pharmaceuticals MuGard Added to Nationally Ranked Childrens Hospital of Colorado Pharmacy Formulary
8. To Take a Glance Cutting Edge Medicine Equipment! The 28th International Medical & Hospital Equipment Show
9. National Data Center Hosting Provider, CoreLink Data Centers, to Present at HIMSS 2012
10. Natural Alternatives International, Inc. Files Patent Infringement Claim Against DNP International Co., Inc.
11. Nationally Recognized Glenveigh Medical Announces Orphan Drug Designation for Treatment for Severe Preeclampsia and Eclampsia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/19/2017)... CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will participate ... the Sheraton Hotel in Toronto, Ontario . ... is scheduled to present on Tuesday, May 2 at 10:00 am. ... the Board, Tony Holler will also attend the event. ... For more details about the ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
Breaking Medicine Technology:
(Date:4/26/2017)... Hackensack, N.J. (PRWEB) , ... April 26, 2017 ... ... fluency, Inc. in Hackensack, N.J. has been honored by Enterprising Women magazine ... program that recognizes the world’s top women business owners. Winners have demonstrated that ...
(Date:4/26/2017)... ... 2017 , ... RawTrition now brings you BioEnergy which is a powder capsule ... , RawTrition is taking nutrients to the next level! The superfoods in ... raw form (unlike the synthetically made options that are on the market). , Founder ...
(Date:4/26/2017)... FL (PRWEB) , ... April 26, 2017 , ... ... and human performance, is proud to announce that it has received 510(k) clearance ... technologies, the MyoCycle Home and the MyoCycle Pro. , Both devices are stationary ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, and ... its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne ...
(Date:4/25/2017)... ... 2017 , ... The doctors at Wall Centre Dental are now expanding their ... require sedation to receive dental care. The doctors offer three treatment options to put ... to oral surgery, at their dental office in Vancouver. Wall Centre Dental is currently ...
Breaking Medicine News(10 mins):